Comanche Biopharma Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway (ILAP) Steering Group for CBP-4888, an Investigational siRNA Drug Candidate for the Treatment of sFlt1-mediated Preterm Preeclampsia
January 30, 2025 05:00 ET | Source: Comanche Biopharma ILAP aims to…
US FDA Grants Orphan Drug Designation to EXG110, a Novel Gene Therapy for Fabry Disease
Company also Provides Updates on wet Age Related Macular Degeneration and Rare…
AlveoGene Receives Rare Pediatric Disease Designation (RPDD)from FDA for AVG-002, its Novel, Inhaled Gene Therapy forLethal Neonatal Surfactant Protein B (SP-B) Deficiency
Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress…